Tislelizumab bridging to umbilical cord blood transplantation therapy for relapsed/refractory acute myeloid leukemia: report of 1 case and review of literature
10.3760/cma.j.cn115356-20220909-00255
- VernacularTitle:替雷利珠单抗桥接脐血移植治疗复发难治急性髓系白血病1例并文献复习
- Author:
Chenchen LIU
1
;
Shiyuan ZHOU
;
Qian ZHU
;
Chao MA
;
Xiao MA
;
Depei WU
;
Xiaojin WU
Author Information
1. 苏州大学附属第一医院血液科 国家血液系统疾病临床医学研究中心 江苏省血液研究所 苏州大学造血干细胞移植研究所 卫生部血栓与止血重点实验室血液学协同创新中心，苏州 215006
- Keywords:
Leukemia, myeloid, acute;
Recurrence;
Refractory;
Tislelizumab;
Immunotherapy;
Salvage therapy;
Cord blood stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2023;32(3):161-165
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of tislelizumab combined with umbilical cord blood transplantation (UCBT) in relapsed/refractory acute myeloid leukemia (R/R AML) patients.Methods:The diagnosis and treatment of 1 patient with R/R AML who received tislelizumab bridging to UCBT after the failure of re-induction treatment in the First Affiliated Hospital of Soochow University in November 2021 was retrospectively analyzed.Results:The 59-year-old male patient with R/R AML achieved a complete remission after initial induction chemotherapy regimen of decitabine and venetoclax, and then additional consolidation therapy regimens of decitabine and middle-dose cytarabine, middle-dose cytarabine and idarubicin were performed. The patient relapsed 16 months later and failed to achieve a second remission after re-induction therapy regimens of cladribine, azacitidine, venetoclax combined with chemotherapy, and homoharringtonine, cytarabine combined with granulocyte colony-stimulating factor. Tislelizumab significantly reduced tumor burden and the patient achieved the complete remission after bridging to UCBT. After transplantation, the patient was given maintenance treatment with azacitidine and he had sustained remission without severe transplant-related complications during 9-month follow-up.Conclusions:The use of tislelizumab bridging UCBT can be a potential therapeutic strategy for R/R AML patients.
